Comparative Pharmacology
Head-to-head clinical analysis: DIAMOX versus ETHAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAMOX versus ETHAMIDE.
DIAMOX vs ETHAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Ethamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, lowering intraocular pressure. It also has diuretic effects by inhibiting carbonic anhydrase in the proximal renal tubule, leading to bicarbonate excretion and metabolic acidosis.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
15-25 mg/kg orally once daily (max 1.5 g/day).
None Documented
None Documented
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Terminal elimination half-life is 4-6 hours in normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; pH-dependent; alkaline urine increases elimination.
Primarily renal (80-90%) as unchanged drug via glomerular filtration and tubular secretion; minor biliary/fecal (<5%) and metabolic (5-10%) elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor